Newest
PEBO ▼ sold $76K · Augenstein Mark filed 1d agoBBT ▲ bought $105K · Hollister Thomas J filed 2d agoBBT ▼ sold $20K · Eagan John Buckley filed 2d agoGS ▼ sold $60K · LESLIE ERICKA T filed 2d agoGS ▼ sold $163K · LESLIE ERICKA T filed 2d agoMSCI ▼ sold $1.5M · Gutowski Robert J. filed 2d agoGL ▼ sold $2.2M · MAJORS MICHAEL CLAY filed 2d agoPHR ▲ bought $362 · Linetsky David filed 2d agoPHR ▲ bought $320 · Linetsky David filed 2d agoRVI ▲ bought $23K · Whitney Meredith filed 2d agoLEO ▲ bought $369K · Saba Capital Management, L.P. filed 2d agoPG ▼ sold $5.7M · Jejurikar Shailesh filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoICLR ▼ sold $15K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoPG ▼ sold $698K · Gama Paul filed 2d ago

Insider / Quantinuum Inc.

Hazra Rajeeb

President & CEO at Quantinuum Inc.

Company
Quantinuum Inc.
Ticker
QNT
First filing on record
June 8, 2026
Latest trade on record
June 4, 2026
SEC filings
EDGAR ↗

Hazra Rajeeb, President & CEO at Quantinuum Inc., has disclosed 4 transactions in QNT since June 8, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $20.2M at the reported prices. The latest was filed June 8, 2026, 5 days after the trade; 3 filings were late against the 2-business-day Form 4 deadline.

Last updated June 8, 2026 · Source: SEC EDGAR Form 4 filings

Transactions
4
Open-market buys
0
Sales
1
Avg. disclosure lag
4.8d

Trading in charts

Trade timeline

When does this person trade, how big, and in which direction? Every trade in the last 12 months.

Bought (above the line)Sold (below the line)Other transaction
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep

In the last 12 months Hazra Rajeeb made no purchases and 1 sale worth $20M, plus 3 other transactions. Dot size is the dollar amount.

Portfolio mix

Which stocks does this person trade most? Tile size is dollars traded, all time on record.

Hazra Rajeeb has traded 1 stock on record; the largest by dollars is QNT.

What kind of transactions

Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.

Rows by Form 4 transaction code
CodeMeaningRowsSharesValue
AGrant or award31,243,685—
FShares withheld for tax1336,389$20.2M
Rows by year of the trade
YearRowsBoughtSold
2026401 · $20.2M

Transactions

Download QNT trades (CSV)27 rows · 9 KB · every filer in this ticker, this insider included · all downloads

SecuritySideTrade dateDisclosedLagSharesPriceValueFlagsSourceShare
QNTOther AJune 3, 2026June 8, 20265d122,791——latederivativeForm 4 ↗
QNTOther AJune 4, 2026June 8, 20264d78,333——Form 4 ↗
QNTSell FJune 3, 2026June 8, 20265d336,389$60$20.2MlateForm 4 ↗
QNTOther AJune 3, 2026June 8, 20265d1,042,561——lateForm 4 ↗

Filings

FiledFormAccessionRowsStatusSource
June 8, 2026Form 40001628280-26-0416204publishedEDGAR ↗

Other insiders at Quantinuum Inc.

Everyone on file, with contracts and lobbying under the company's name: Quantinuum Inc..

Guides for this page

Sources and method

Official sources behind this page
SourceFilingsRowsFirst filedNewest filedRead the originals
SEC EDGAR, Form 414June 8, 2026June 8, 2026Form 4 list on EDGAR

Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.

Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.

Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.